Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03594227 · ClinicalTrials.gov registry record · Phase 2
ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis
A Phase 2 study, sponsored by Aclaris Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 87
- Enrollment target
NCT03594227 is a Phase 2 study that has completed, run by Aclaris Therapeutics. The registered enrollment target is 87 participants.
The verdict
NCT03594227, a Phase 2 study, has completed, sponsored by Aclaris Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 87 participants
- Enrollment target
Study Summary
This Phase 2, multicenter, randomized study will evaluate the safety, tolerability and efficacy of ATI-501 for the treatment of Alopecia Areata (AA), Alopecia Universalis (AU) or Alopecia Totalis (AT) in adult subjects.
Interventions
- DRUG Placebo
- DRUG ATI-501 400mg BID (Low dose)
- DRUG ATI-501 600mg BID (Mid dose)
- DRUG ATI-501 800mg BID (High dose)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2018-06-11 |
| Est. Completion | 2019-06-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03594227
The ClinicalTrials.gov registry entry for NCT03594227 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aclaris Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT03594227 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03594227 about?
NCT03594227 is a clinical study titled "ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis". This Phase 2, multicenter, randomized study will evaluate the safety, tolerability and efficacy of ATI-501 for the treatment of Alopecia Areata (AA), Alopecia Universalis (AU) or Alopecia Totalis (AT) in adult subjects.
What is the current status of trial NCT03594227?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2018-06-11. Estimated completion is 2019-06-18.
What interventions are being tested in trial NCT03594227?
The interventions under investigation include: Placebo (DRUG), ATI-501 400mg BID (Low dose) (DRUG), ATI-501 600mg BID (Mid dose) (DRUG), ATI-501 800mg BID (High dose) (DRUG).
Who is sponsoring clinical trial NCT03594227?
This trial is sponsored by Aclaris Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.